Targeting Bromodomains: Epigenetic Readers of Lysine Acetylation

Overview

Journal Nat Rev Drug Discov

Specialty Pharmacology

Date 2014 Apr 23

PMID 24751816

Citations 553

Authors

Panagis Filippakopoulos

Stefan Knapp

Affiliations

Soon will be listed here.

Abstract

Lysine acetylation is a key mechanism that regulates chromatin structure; aberrant acetylation levels have been linked to the development of several diseases. Acetyl-lysine modifications create docking sites for bromodomains, which are small interaction modules found on diverse proteins, some of which have a key role in the acetylation-dependent assembly of transcriptional regulator complexes. These complexes can then initiate transcriptional programmes that result in phenotypic changes. The recent discovery of potent and highly specific inhibitors for the BET (bromodomain and extra-terminal) family of bromodomains has stimulated intensive research activity in diverse therapeutic areas, particularly in oncology, where BET proteins regulate the expression of key oncogenes and anti-apoptotic proteins. In addition, targeting BET bromodomains could hold potential for the treatment of inflammation and viral infection. Here, we highlight recent progress in the development of bromodomain inhibitors, and their potential applications in drug discovery.

Citing Articles

Revolutionary Cancer Therapy for Personalization and Improved Efficacy: Strategies to Overcome Resistance to Immune Checkpoint Inhibitor Therapy.

Almawash S Cancers (Basel). 2025; 17(5).

PMID: 40075727 PMC: 11899125. DOI: 10.3390/cancers17050880.

Advancing Understanding and Therapeutic Strategies for NUT Sarcomas: Comprehensive Review of the Literature and Two Cases.

Torrado C, Nassif Haddad E, Somaiah N, Msaouel P, Lazar A, Piha-Paul S J Immunother Precis Oncol. 2025; 8(2):113-120.

PMID: 40070529 PMC: 11896019. DOI: 10.36401/JIPO-24-28.

NLRP3-inflammasome Related Genes as Emerging Biomarkers and Therapeutic Targets in Psoriasis.

Shi A, Shu Y, Hu K, Sudesh S, Tu Y Inflammation. 2025; .

PMID: 40029502 DOI: 10.1007/s10753-025-02271-y.

Harnessing Epigenetics: Innovative Approaches in Diagnosing and Combating Viral Acute Respiratory Infections.

Saha A, Ganguly A, Kumar A, Srivastava N, Pathak R Pathogens. 2025; 14(2).

PMID: 40005506 PMC: 11858160. DOI: 10.3390/pathogens14020129.

Epigenetic regulation of angiogenesis and its therapeutics.

Choi D Genomics Inform. 2025; 23(1):4.

PMID: 39934895 PMC: 11817428. DOI: 10.1186/s44342-025-00038-3.

References

Gehling V, Hewitt M, Vaswani R, LeBlanc Y, Cote A, Nasveschuk C . Discovery, Design, and Optimization of Isoxazole Azepine BET Inhibitors. ACS Med Chem Lett. 2014; 4(9):835-40. PMC: 4027525. DOI: 10.1021/ml4001485. View

Zou Z, Huang B, Wu X, Zhang H, Qi J, Bradner J . Brd4 maintains constitutively active NF-κB in cancer cells by binding to acetylated RelA. Oncogene. 2013; 33(18):2395-404. PMC: 3913736. DOI: 10.1038/onc.2013.179. View

Belkina A, Denis G . BET domain co-regulators in obesity, inflammation and cancer. Nat Rev Cancer. 2012; 12(7):465-77. PMC: 3934568. DOI: 10.1038/nrc3256. View

Kouzarides T . Chromatin modifications and their function. Cell. 2007; 128(4):693-705. DOI: 10.1016/j.cell.2007.02.005. View

Chaidos A, Caputo V, Gouvedenou K, Liu B, Marigo I, Chaudhry M . Potent antimyeloma activity of the novel bromodomain inhibitors I-BET151 and I-BET762. Blood. 2013; 123(5):697-705. DOI: 10.1182/blood-2013-01-478420. View

Stewart H, Horne G, Bastow S, Chevassut T . BRD4 associates with p53 in DNMT3A-mutated leukemia cells and is implicated in apoptosis by the bromodomain inhibitor JQ1. Cancer Med. 2014; 2(6):826-35. PMC: 3892387. DOI: 10.1002/cam4.146. View

Ferguson F, Fedorov O, Chaikuad A, Philpott M, Muniz J, Felletar I . Targeting low-druggability bromodomains: fragment based screening and inhibitor design against the BAZ2B bromodomain. J Med Chem. 2013; 56(24):10183-7. PMC: 3905694. DOI: 10.1021/jm401582c. View

Tamkun J, Deuring R, Scott M, Kissinger M, Pattatucci A, Kaufman T . brahma: a regulator of Drosophila homeotic genes structurally related to the yeast transcriptional activator SNF2/SWI2. Cell. 1992; 68(3):561-72. DOI: 10.1016/0092-8674(92)90191-e. View

Chung C, Dean A, Woolven J, Bamborough P . Fragment-based discovery of bromodomain inhibitors part 1: inhibitor binding modes and implications for lead discovery. J Med Chem. 2011; 55(2):576-86. DOI: 10.1021/jm201320w. View

10.

Berkovits B, Wolgemuth D . The first bromodomain of the testis-specific double bromodomain protein Brdt is required for chromocenter organization that is modulated by genetic background. Dev Biol. 2011; 360(2):358-68. PMC: 3217133. DOI: 10.1016/j.ydbio.2011.10.005. View

11.

Vidler L, Filippakopoulos P, Fedorov O, Picaud S, Martin S, Tomsett M . Discovery of novel small-molecule inhibitors of BRD4 using structure-based virtual screening. J Med Chem. 2013; 56(20):8073-88. PMC: 3807807. DOI: 10.1021/jm4011302. View

12.

Schwartz B, Hofer M, Lemieux M, Bauer D, Cameron M, West N . Differentiation of NUT midline carcinoma by epigenomic reprogramming. Cancer Res. 2011; 71(7):2686-96. PMC: 3070805. DOI: 10.1158/0008-5472.CAN-10-3513. View

13.

Delmore J, Issa G, Lemieux M, Rahl P, Shi J, Jacobs H . BET bromodomain inhibition as a therapeutic strategy to target c-Myc. Cell. 2011; 146(6):904-17. PMC: 3187920. DOI: 10.1016/j.cell.2011.08.017. View

14.

Yang Z, Yik J, Chen R, He N, Jang M, Ozato K . Recruitment of P-TEFb for stimulation of transcriptional elongation by the bromodomain protein Brd4. Mol Cell. 2005; 19(4):535-45. DOI: 10.1016/j.molcel.2005.06.029. View

15.

Picaud S, da Costa D, Thanasopoulou A, Filippakopoulos P, Fish P, Philpott M . PFI-1, a highly selective protein interaction inhibitor, targeting BET Bromodomains. Cancer Res. 2013; 73(11):3336-46. PMC: 3673830. DOI: 10.1158/0008-5472.CAN-12-3292. View

16.

Gregory G, Vakoc C, Rozovskaia T, Zheng X, Patel S, Nakamura T . Mammalian ASH1L is a histone methyltransferase that occupies the transcribed region of active genes. Mol Cell Biol. 2007; 27(24):8466-79. PMC: 2169421. DOI: 10.1128/MCB.00993-07. View

17.

Jacobson R, Ladurner A, King D, Tjian R . Structure and function of a human TAFII250 double bromodomain module. Science. 2000; 288(5470):1422-5. DOI: 10.1126/science.288.5470.1422. View

18.

Groisman R, Naguibneva I, Robin P, Lorain S, Le Villain J, Troalen F . Retinoblastoma protein represses transcription by recruiting a histone deacetylase. Nature. 1998; 391(6667):601-5. DOI: 10.1038/35410. View

19.

Wyspianska B, Bannister A, Barbieri I, Nangalia J, Godfrey A, Calero-Nieto F . BET protein inhibition shows efficacy against JAK2V617F-driven neoplasms. Leukemia. 2013; 28(1):88-97. DOI: 10.1038/leu.2013.234. View

20.

Herrmann H, Blatt K, Shi J, Gleixner K, Cerny-Reiterer S, Mullauer L . Small-molecule inhibition of BRD4 as a new potent approach to eliminate leukemic stem- and progenitor cells in acute myeloid leukemia AML. Oncotarget. 2012; 3(12):1588-99. PMC: 3681497. DOI: 10.18632/oncotarget.733. View